Current financial headlines

Sharemaestro Newsreel

Financial news from across the world, newest first. Choose a country or market group, open the source, or continue into the company data.

Showing
1–11
Headlines
11
Sources here
3
Companies here
5
Current section Austria Biotechnology news
Latest

finance.yahoo.com Earnings

BMRN vs. ILMN: Which Stock Is the Better Value Option?

Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either BioMarin Pharmaceutical (BMRN) or Illumina (ILMN). But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look. We have found that the best way to discover great value opportunities is to …

BioMarin Pharmaceutical (BMRN) Stock Is Up, What You Need To Know

BioMarin Pharmaceutical (BMRN) Stock Is Up, What You Need To Know What Happened? Shares of biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) jumped 2.6% in the morning session after an analyst at Canaccord Genuity raised the company's price target to $114 from $111 and maintained a …

BMRN main company
Sharemaestro market context Trend signal active 52 weeks +11.5% · Next-week setup negative 38.4% BMRN stored weekly price path from 15 Aug 2025 to 7 Aug 2026

BioMarin Targets Faster Deleveraging as Amicus Deal Expands Rare-Disease Growth

Key Points Interested in BioMarin Pharmaceutical Inc.? Here are five stocks we like better. BioMarin raised its financial outlook after second-quarter revenue approached $1 billion, lifting 2025 revenue guidance to $3.875 billion–$3.925 billion and non-GAAP EPS guidance to $4.90–$5.10. The Amicus acquisition added Galafold …

BMRN main company
Sharemaestro market context Trend signal active 52 weeks +11.5% · Next-week setup negative 38.4% BMRN stored weekly price path from 15 Aug 2025 to 7 Aug 2026

Chronological news

Latest headlines

External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.

REGN Soars 21.9% in a Month: Buy, Sell or Hold the Stock?

The going has been strong for Regeneron Pharmaceuticals REGN over the past month. Shares of this biotech giant have surged 21.9% over the said time frame, outpacing the industry's growth of 4%. The stock has also outperformed the sector and the S&P 500 Index …

REGN main company
Sharemaestro market context Price above Trend Line 52 weeks +38.7% REGN stored weekly price path from 15 Aug 2025 to 7 Aug 2026

argenx (ENXTBR:ARGX) Stock Looks Fully Valued Despite Strong Returns And Deal Hopes

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. argenx stock has delivered a strong long term return over the past five years, yet the current valuation checks and recent acquisition plans raise questions about how …

ARGX main company
Sharemaestro market context Trend signal active 52 weeks +39.3% ARGX stored weekly price path from 15 Aug 2025 to 7 Aug 2026

Could Arbutus Biopharma Corporation (ABUS) Turn its Moderna, Inc. (MRNA) Settlement Into a Lasting Biotech Advantage?

A landmark legal settlement in the biotech sector recently reshaped the financial trajectories of two key mRNA technology players: Arbutus Biopharma Corporation (NASDAQ:ABUS) and Moderna, Inc. (NASDAQ:MRNA). The resolution of their global patent infringement litigation over lipid nanoparticle (LNP) delivery technology provided Arbutus with …

MRNA main company
Sharemaestro market context Trend signal active 52 weeks +108.3% MRNA stored weekly price path from 15 Aug 2025 to 7 Aug 2026

Lakefront Biotherapeutics Reports Half-Year 2026 Financial Results and Provides Business Update

Lakefront Biotherapeutics Completed acquisition of Ouro Medicines with Gilead Sciences to advance potential first and best-in-class T-cell engager Forecast at least €1.6B of cash remaining after funding portfolio to first gamgertamig approval Maintain year-end 2026 cash and financial investments balance guidance of ~€2B, and …

LKFT main company
Sharemaestro market context Price below Trend Line 52 weeks -15.6% LKFT stored weekly price path from 15 Aug 2025 to 7 Aug 2026

BioMarin to Participate at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026, at 8:00AM ET in Boston

SAN RAFAEL, Calif., Aug. 10, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced management will present at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026, at 8:00AM ET in Boston.BioMarin Pharmaceutical logo An audio webcast of the presentation …

BMRN main company
Sharemaestro market context Trend signal active 52 weeks +11.5% · Next-week setup negative 38.4% BMRN stored weekly price path from 15 Aug 2025 to 7 Aug 2026

Bronstein, Gewirtz & Grossman LLC Urges Regeneron Pharmaceuticals, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

NEW YORK, Aug. 09, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and certain of its officers. This lawsuit seeks to recover …

REGN main company
Sharemaestro market context Price above Trend Line 52 weeks +38.7% REGN stored weekly price path from 15 Aug 2025 to 7 Aug 2026

Regeneron Pharmaceuticals (REGN) Keeps Buybacks And Dividend In Focus As Fair Value Stays In Sight

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Dividend, earnings and buybacks in focus Regeneron Pharmaceuticals (REGN) has given investors several fresh data points to consider after confirming a quarterly dividend, releasing …

REGN main company
Sharemaestro market context Price above Trend Line 52 weeks +38.7% REGN stored weekly price path from 15 Aug 2025 to 7 Aug 2026

Moderna (MRNA) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Friday, July 31, 2026 at 8:00 a.m. ET CALL PARTICIPANTS Chief Executive Officer - Stphane BancelPresident - Stephen HogeChief Financial Officer - James MockChief Development Officer - David Berman TAKEAWAYS Total Revenue -- $145 million, representing 2% growth …

MRNA main company
Sharemaestro market context Trend signal active 52 weeks +108.3% MRNA stored weekly price path from 15 Aug 2025 to 7 Aug 2026

Find financial news

Search the Newsreel

Use one field or combine several. Results are newest first.

Evidence context